Immutep Limited (IMMP): history, ownership, mission, how it works & makes money

A Brief History of Immutep Limited (IMMP)

Company Formation

Immutep Limited was established in 2001, originally as a biotechnology company focused on the development of cancer immunotherapy treatments. The company is headquartered in Sydney, Australia, with additional offices in the United States.

Key Developments

Immutep is known for its innovative work in the area of LAG-3 (Lymphocyte Activation Gene 3) protein. The company has developed a range of products utilizing this technology, which is aimed at enhancing the body's immune response against cancer cells.

Financial Overview

As of October 2023, Immutep reported a market capitalization of approximately AUD 162 million. For the fiscal year ending June 30, 2023, the company reported a revenue of AUD 3.5 million from grants and collaborations. The total expenses for the same period were AUD 22.1 million, resulting in a net loss of AUD 18.6 million.

Key Partnerships

Immutep has entered into strategic collaborations with various pharmaceutical companies. Notably, a partnership with Merck KGaA and Pfizer for a clinical trial involving their drug, aLAG-3, has been significant. These collaborations focus on developing therapies for various cancers, including non-small cell lung cancer and breast cancer.

Clinical Trials

• Clinical trial phase for aLAG-3 in combination with pembrolizumab (Keytruda) started in 2021.
• Phase II trial conducted for metastatic breast cancer showing promising results.
• Ongoing trials for various indications and multiple combinations with other therapies.

Recent Achievements

In September 2023, Immutep announced positive results from their clinical study of eftilagimod alpha (efti), revealing a significant increase in progression-free survival in patients with head and neck cancer. The results were presented at the European Society for Medical Oncology (ESMO) Congress 2023.

Future Directions

Looking forward, Immutep is focused on advancing its clinical programs and expanding its pipeline of immunotherapy agents. The company aims to continue leveraging its LAG-3 technology to develop novel therapeutics, with plans to initiate additional clinical trials in 2024 and beyond.

A Who Owns Immutep Limited (IMMP)

Shareholding Structure

The ownership of Immutep Limited (ASX: IMMP) is characterized by a diverse range of shareholders, including institutional investors, retail investors, and company insiders. As of the latest filings on October 2023, the shareholding structure is as follows:

Major Shareholders

The following table highlights the major shareholders who own significant stakes in Immutep Limited:

Market Capitalization

The market capitalization of Immutep Limited as of October 2023 is approximately $420 million, calculated based on its share price of $0.84 and total shares outstanding of 500 million.

Recent Financial Performance

For the fiscal year ending June 2023, Immutep reported the following financial results:

Ownership Trends

Over the last year, ownership trends indicate the following changes:

• Institutional ownership increased by 5% from previous year.
• Retail ownership decreased by 10% due to broader market volatility.
• Insider holdings remained relatively stable over the year.

Regulatory Filings

Immutep Limited is required to file disclosures regarding its ownership structure and any significant changes with the Australian Securities and Investments Commission (ASIC). The latest Form 484 highlights the following:

Conclusion on Ownership Dynamics

The ownership dynamics of Immutep Limited indicate a robust interest from institutional investors while maintaining a diverse base of retail and insider ownership. In navigating financial challenges, the company is strategically positioned to leverage its ownership structure to support ongoing R&D initiatives and growth potential.

Immutep Limited (IMMP) Mission Statement

Overview

Immutep Limited is a biotechnology company focused on developing innovative immunotherapies to treat cancer and autoimmune diseases. The mission statement emphasizes the commitment to advancing immunotherapy and improving patient outcomes through research and development.

Core Elements of the Mission Statement

• Innovation: Pioneering new treatments through cutting-edge technology.
• Patient-Centric Approach: Focusing on improving the quality of life for patients.
• Collaboration: Working with global partners to accelerate research and development.
• Integrity: Upholding ethical standards in all business practices.

Strategic Goals

Immutep is aligned with several strategic goals that guide its mission:

• Development Pipeline: Targeting multiple indications with lead assets in clinical trials, including Eftilagimod Alpha.
• Market Expansion: Seeking to expand into international markets to broaden access to therapies.
• Financial Sustainability: Building a strong financial foundation to support long-term research efforts.

Recent Financial Performance

Clinical Development

The company has several ongoing clinical trials aimed at evaluating its therapies:

• Phase 2 trial of Eftilagimod Alpha in combination with other therapies.
• Partnership with major pharmaceutical companies for collaborative studies.
• Focus on novel combinations to enhance immunotherapy efficacy.

Partnerships and Collaborations

Immutep has established various collaborations to bolster its research capabilities:

• Partnership with Merck KGaA for the development of LAG-3 products.
• Collaborations with academic institutions for joint research initiatives.
• Engagements with regulatory bodies to streamline the approval processes.

Future Outlook

Looking forward, Immutep aims to:

• Initiate new clinical trials for its pipeline candidates by 2024.
• Enhance its financial position through strategic investments.
• Strengthen its global presence, particularly in Europe and North America.

How Immutep Limited (IMMP) Works

Company Overview

Immutep Limited (ASX: IMMP) is a biopharmaceutical company engaged in developing novel immunotherapeutic products for the treatment of cancer and autoimmune diseases. Established in 2001, the company is headquartered in Sydney, Australia, and operates in the clinical development space.

Key Products

Immutep's lead product candidates include:

• eftilagimod alpha (IMP321): A soluble LAG-3 protein that is undergoing trials for various cancer types.
• IMP701: An anti-PD-1 monoclonal antibody that targets immune checkpoints.
• IMP731: A treatment for autoimmune diseases targeting LAG-3 and PD-1 pathways.

Clinical Trials

As of October 2023, Immutep is involved in multiple clinical trials:

Financial Performance

For the financial year ended June 30, 2023, Immutep reported the following financial data:

Market Performance

As of October 2023, the stock price of Immutep Limited is approximately AUD 0.85, with a market capitalization of around AUD 160 million.

The company has shown a year-to-date performance of +25%, reflecting investor interest in its clinical pipeline.

Collaborations and Partnerships

Immutep has entered into strategic collaborations:

• Partnership with Merck: Focused on the combination of IMP701 with Merck’s KEYTRUDA in ongoing trials.
• Collaboration with GSK: Exploring the use of LAG-3 in autoimmune indications.

Future Outlook

The company is aiming to expand its development programs and plans to conduct pivotal trials for its lead compounds. Future milestones include:

• Anticipated data readouts from ongoing clinical trials in 2024.
• Exploration of strategic partnerships for commercialization.
• Continued investment in research and development to enhance its pipeline.

How Immutep Limited (IMMP) Makes Money

Revenue Streams

Immutep Limited (IMMP) generates revenue primarily through partnerships, licensing agreements, and clinical development programs. The company focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases.

Partnerships and Collaborations

Immutep has established various partnerships with pharmaceutical companies and research institutions, allowing for shared resources and risk mitigation. For instance, the collaboration with Merck KGaA is designed to enhance the development of their lead product candidate, Efti, for various oncology indications.

Licensing Agreements

The company also enters into licensing agreements which can provide upfront payments as well as milestone payments and royalties. These agreements offer a consistent revenue stream while minimizing the cost burden of drug development.

Clinical Development Program Funding

Immutep’s clinical trials, particularly in Phase II and III, can attract funding from government grants or larger pharmaceutical companies looking to co-develop drugs. This can lead to significant financial inflows. In 2022, the company reported $6.3 million in R&D co-funding from various clinical trials.

Product Pipeline

Immutep's product pipeline includes:

• Efti (IMP321): Undergoing clinical trials for metastatic breast cancer, lymphoma, and head and neck cancer.
• APC-activated immunotherapy: Aiming to enhance patient immune response.
• Combination therapies: Exploring synergies with checkpoint inhibitors.

Financial Summary

Market Opportunities

The global immunotherapy market is projected to reach USD 115.38 billion by 2028, growing at a CAGR of 11.4% from 2021. Immutep’s focus on the T-cell activation pathway positions it well within this expanding market.

Regulatory Milestones

Regulatory approvals can significantly impact revenue streams. Immutep is targeting submissions for various indications, aiming for European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) approvals within the next two years.

Investor Interest

As of October 2023, Immutep's share price is approximately AUD 0.70, reflecting a market capitalization of around AUD 266 million. Investor sentiment can drive funding for continued research and development.